A Registry-study of ELZONRIS in Participants With BPDCN

NCT07785154 · tracked via the Priya Life Science Germany tracker

Sponsor

Stemline Therapeutics, Inc

Phase

Observational

Started

2024-06-26

Last updated

2026-08-25

Condition(s) studied

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Investigational drug(s) / intervention(s)

Tagraxofusp →

Tagraxofusp: No study medication will be provided by the sponsor during this study.

Study summary

The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Key Inclusion Criteria: * Diagnosed with BPDCN, confirmed by hematopathology and biomarkers (inclusive of CD123, CD4, and CD56). * Planning to start treatment with tagraxofusp monotherapy for BPDCN at the time of, or within 6 months prior to, informed consent form (ICF) signature or has started treatment. Key Exclusion Criteria: * Currently (or planning to) participating in another study or registry where BPDCN treatment outcomes are reported. * Participating in an interventional clinical trial at the time of ICF signature. * Known allergic reactions to components of tagraxofusp. Note: Other protocol-specified criteria apply.

Primary outcome measure(s)

Number of Participants Achieving Complete Response After 3 Months (+/- 1 month) of Treatment — Up to Month 4
Number of Participants Experiencing Capillary Leak Syndrome — Up to Month 51

Trial sites (41)

Facility	City	Region	Status
Medical University Innsbruck	Innsbruck	Austria	Recruiting
Ordensklinikum Linz Krankenhaus der Elisabethinen Linz	Linz	Austria	Recruiting
Salzburg Cancer Research Institute (SCRI)	Salzburg	Austria	Recruiting
Medizinische Universitat Wien, Department for Internal Medicine I, Division of Hematology and Haemostaseology	Vienna	Austria	Recruiting
Universitätsklinikum Augsburg	Augsburg	Germany	Recruiting
Hospital Bielefeld	Bielefeld	Germany	Recruiting
Klinikum Chemnitz	Chemnitz	Germany	Recruiting
University Clinic of Frankfurt	Frankfurt	Germany	Recruiting
University clinic of Freiburg	Freiburg im Breisgau	Germany	Recruiting
Universitätsmedizin Halle	Halle	Germany	Recruiting
Asklepios Hamburg	Hamburg	Germany	Recruiting
University Medical Center Hamburg - Eppendorf	Hamburg	Germany	Recruiting
Community Hospital Kiel	Kiel	Germany	Recruiting
Universitätsklinikum Leipzig Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie	Leipzig	Germany	Recruiting
Universitätsklinikum Schleswig-Holstein	Lübeck	Germany	Recruiting
Technical University of Munich	Munich	Germany	Recruiting
Oldenburgh	Oldenburg	Germany	Recruiting
Medizinische Klinik Universitat Tübingen	Tübingen	Germany	Recruiting
AON SS Antonio e Biagio e C Arrigo Alessandria SOC Ematologia	Alessandria	Italy	Recruiting
AOU di Bologna - Policlinico S. Orsola-Malpighi - UOC Ematologia	Bologna	Italy	Recruiting
CTC U.O di Ematologia con Trapianto di Midollo Osseo - Catania	Catania	Italy	Recruiting
ASO S. Croce e Carle - Cuneo - SC Ematologia	Cuneo	Italy	Recruiting
AOU Arcispedale Sant'Anna Cona (FE) - UOC Ematologia e Fisiopatologia della Coagulazione	Ferrara	Italy	Recruiting
AOU Careggi - Firenze - SOD Ematologia	Florence	Italy	Recruiting
IRCCS AOU San Martino - Genova - UO Clinica Ematologica	Genova	Italy	Recruiting
UO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino - Genoa	Genova	Italy	Recruiting
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Milano - Ematologia	Milan	Italy	Recruiting
SC Ematologia - ASST Grande Ospedale Metropolitano Niguarda	Milan	Italy	Recruiting
AOU Federico II - UOC Ematologia e Trapianti di Midollo	Naples	Italy	Recruiting
AOU di Padova - UO Ematologia	Padova	Italy	Recruiting
AO Ospedali Riuniti Villa Sofia Cervello Palermo - UO Ematologia con UTMO	Palermo	Italy	Recruiting
Fondazione IRCCS Policlinico San Matteo Pavia UO Ematologia	Pavia	Italy	Recruiting
AO di Perugia, Ospedale S. Maria della Misericordia - Ematologia E Trapianto Midollo Osseo	Perugia	Italy	Recruiting
ASL Pescara - Presidio Ospedaliero "Spirito Santo" - UOC Ematologia Clinica	Pescara	Italy	Recruiting
AOU Policlinico Tor Vergata - Roma - Ematologia	Roma	Italy	Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Roma - Area Ematologica	Roma	Italy	Recruiting
AOU 'San Giovanni di Dio e Ruggi d'Aragona' Salerno - UOC Ematologia	Salerno	Italy	Recruiting
AOU Città della Salute e della Scienza - Ospedale S. G. Battista Molinette - Torino - SC Ematologia	Torino	Italy	Recruiting
ASUI di Udine - Presidio Ospedaliero "Santa Maria della Misericordia" - Clinica Ematologica	Udine	Italy	Recruiting
Insel Gruppe AG, Bern University Hospital	Bern	Switzerland	Recruiting

+ 1 more sites — see the full list on the official registry below.

More Stemline Therapeutics, Inc. trials in Germany

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence Recruiting

Other trials for the same condition

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07785154 on ClinicalTrials.gov ↗ ← All trials in Germany